Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. more
Time Frame | SNOA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.41% | -0.33% | -1.49% |
1-Month Return | -6.83% | -4.57% | -0.37% |
3-Month Return | -17.52% | -9.96% | 3.89% |
6-Month Return | -28.08% | -5.67% | 9.34% |
1-Year Return | -31.92% | 2.53% | 25.19% |
3-Year Return | -97.16% | -1.43% | 24.7% |
5-Year Return | -96.75% | 34.73% | 85.39% |
10-Year Return | -99.8% | 102.14% | 187.19% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 18.94M | 18.63M | 12.63M | 13.27M | 12.73M | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":98.38,"profit":true},{"date":"2022-03-31","value":66.69,"profit":true},{"date":"2023-03-31","value":70.09,"profit":true},{"date":"2024-03-31","value":67.25,"profit":true}] |
Cost of Revenue | 10.60M | 12.07M | 8.63M | 8.79M | 7.99M | [{"date":"2020-03-31","value":87.85,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":71.54,"profit":true},{"date":"2023-03-31","value":72.87,"profit":true},{"date":"2024-03-31","value":66.2,"profit":true}] |
Gross Profit | 8.33M | 6.56M | 3.99M | 4.48M | 4.75M | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":78.71,"profit":true},{"date":"2022-03-31","value":47.92,"profit":true},{"date":"2023-03-31","value":53.73,"profit":true},{"date":"2024-03-31","value":56.94,"profit":true}] |
Gross Margin | 44.01% | 35.21% | 31.62% | 33.73% | 37.26% | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":80.01,"profit":true},{"date":"2022-03-31","value":71.85,"profit":true},{"date":"2023-03-31","value":76.65,"profit":true},{"date":"2024-03-31","value":84.67,"profit":true}] |
Operating Expenses | 15.00M | 10.01M | 9.88M | 9.05M | 9.45M | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":66.7,"profit":true},{"date":"2022-03-31","value":65.85,"profit":true},{"date":"2023-03-31","value":60.3,"profit":true},{"date":"2024-03-31","value":62.96,"profit":true}] |
Operating Income | (6.67M) | (3.45M) | (5.89M) | (4.57M) | (4.70M) | [{"date":"2020-03-31","value":-667100000,"profit":false},{"date":"2021-03-31","value":-344900000,"profit":false},{"date":"2022-03-31","value":-588700000,"profit":false},{"date":"2023-03-31","value":-457000000,"profit":false},{"date":"2024-03-31","value":-470100000,"profit":false}] |
Total Non-Operating Income/Expense | 3.88M | (449.00K) | 459.00K | (598.00K) | - | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-11.57,"profit":false},{"date":"2022-03-31","value":11.83,"profit":true},{"date":"2023-03-31","value":-15.41,"profit":false},{"date":"2024-03-31","value":"-","profit":true}] |
Pre-Tax Income | (2.83M) | (3.90M) | (5.42M) | (5.18M) | (5.03M) | [{"date":"2020-03-31","value":-282500000,"profit":false},{"date":"2021-03-31","value":-390200000,"profit":false},{"date":"2022-03-31","value":-541800000,"profit":false},{"date":"2023-03-31","value":-518400000,"profit":false},{"date":"2024-03-31","value":-503100000,"profit":false}] |
Income Taxes | 121.00K | 713.00K | (332.00K) | (33.00K) | (196.00K) | [{"date":"2020-03-31","value":16.97,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-46.56,"profit":false},{"date":"2023-03-31","value":-4.63,"profit":false},{"date":"2024-03-31","value":-27.49,"profit":false}] |
Income After Taxes | (2.95M) | (4.62M) | (5.09M) | (5.15M) | - | [{"date":"2020-03-31","value":-294600000,"profit":false},{"date":"2021-03-31","value":-461500000,"profit":false},{"date":"2022-03-31","value":-508600000,"profit":false},{"date":"2023-03-31","value":-515100000,"profit":false},{"date":"2024-03-31","value":"-","profit":true}] |
Income From Continuous Operations | (2.95M) | (4.62M) | (5.09M) | (5.15M) | (4.83M) | [{"date":"2020-03-31","value":-294600000,"profit":false},{"date":"2021-03-31","value":-461500000,"profit":false},{"date":"2022-03-31","value":-508600000,"profit":false},{"date":"2023-03-31","value":-515100000,"profit":false},{"date":"2024-03-31","value":-483500000,"profit":false}] |
Income From Discontinued Operations | 665.00K | 665.00K | - | - | - | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (2.95M) | (4.62M) | (5.09M) | (5.15M) | (4.83M) | [{"date":"2020-03-31","value":-294600000,"profit":false},{"date":"2021-03-31","value":-461500000,"profit":false},{"date":"2022-03-31","value":-508600000,"profit":false},{"date":"2023-03-31","value":-515100000,"profit":false},{"date":"2024-03-31","value":-483500000,"profit":false}] |
EPS (Diluted) | 11.96 | (0.24) | - | (2.42) | (0.72) | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-2.04,"profit":false},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-20.23,"profit":false},{"date":"2024-03-31","value":-6.01,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SNOA | |
---|---|
Cash Ratio | 1.23 |
Current Ratio | 3.69 |
Quick Ratio | 2.84 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SNOA | |
---|---|
ROA (LTM) | -19.59% |
ROE (LTM) | -74.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SNOA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.61 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.39 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SNOA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.29 |
P/B | 0.68 |
Price/FCF | 11 |
EV/R | 0.14 |
EV/Ebitda | NM |
PEG | NM |
Sonoma Pharmaceuticals Inc (SNOA) share price today is $2.73
Yes, Indians can buy shares of Sonoma Pharmaceuticals Inc (SNOA) on Vested. To buy Sonoma Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SNOA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sonoma Pharmaceuticals Inc (SNOA) via the Vested app. You can start investing in Sonoma Pharmaceuticals Inc (SNOA) with a minimum investment of $1.
You can invest in shares of Sonoma Pharmaceuticals Inc (SNOA) via Vested in three simple steps:
The 52-week high price of Sonoma Pharmaceuticals Inc (SNOA) is $9.37. The 52-week low price of Sonoma Pharmaceuticals Inc (SNOA) is $2.44.
The price-to-earnings (P/E) ratio of Sonoma Pharmaceuticals Inc (SNOA) is
The price-to-book (P/B) ratio of Sonoma Pharmaceuticals Inc (SNOA) is 0.68
The dividend yield of Sonoma Pharmaceuticals Inc (SNOA) is 0.00%
The market capitalization of Sonoma Pharmaceuticals Inc (SNOA) is $3.59M
The stock symbol (or ticker) of Sonoma Pharmaceuticals Inc is SNOA